HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
暂无分享,去创建一个
I. Hung | M. Yuen | D. Wong | J. Fung | P. Ip | D. But | K. P. Lau | J. Yuen | Ching-lung Lai | Ching‐lung Lai
[1] R. Sampliner,et al. The Liver Histology and Frequency of Clearance of the Hepatitis B Surface Antigen (HBsAg) in Chronic Carriers , 1979, The American journal of the medical sciences.
[2] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[3] B. McMahon,et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. , 1985, The Journal of infectious diseases.
[4] H. Hsu,et al. Clearance of hepatitis B surface antigen (HBsAg) after surgical resection of hepatocellular carcinoma. , 1987, Journal of hepatology.
[5] M. Loriot,et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. , 1990, Annals of internal medicine.
[6] B. McMahon,et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. , 1990, Archives of internal medicine.
[7] C. Chu,et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study , 1991, Hepatology.
[8] S. Kaneko,et al. Clearance of HBsAg in seven patients with chronic hepatitis B , 1992, Hepatology.
[9] H. Hsu,et al. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection , 1992, Hepatology.
[10] A. Mason,et al. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. , 1992, Gastroenterology.
[11] J. Hoofnagle,et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B , 1993, Hepatology.
[12] M. Loriot,et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. , 1997, Journal of hepatology.
[13] L. Mimms,et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia , 1997, Hepatology.
[14] M. Yu,et al. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non‐Asians in Los Angeles County, California , 1997 .
[15] S. Wirth,et al. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. , 1997, Journal of hepatology.
[16] F. Chang,et al. Sero‐clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis , 1998, Hepatology.
[17] G. Fattovich,et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998, American Journal of Gastroenterology.
[18] Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis , 1998 .
[19] I. Mushahwar,et al. Immunoassay detection of hepatitis B surface antigen mutants , 1999, Journal of medical virology.
[20] H. Kawasaki,et al. Occult hepatitis B virus infection in HBs antigen‐negative hepatocellular carcinoma in a Japanese population: Involvement of HBx and p53 , 2000, Journal of medical virology.
[21] M. Komori,et al. Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients. , 2001, Journal of hepatology.
[22] C. Bréchot,et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? , 2001, Hepatology.
[23] C. Chu,et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.
[24] C. Siu,et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects , 2004, Hepatology.
[25] C. Gibbs,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.
[26] Y. N. Park,et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. , 2005, Journal of hepatology.
[27] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[28] Yoshiyuki Suzuki,et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. , 2006, The American journal of medicine.
[29] Ching-Lung Lai,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.
[30] M. Yuen,et al. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. , 2006, Journal of hepatology.
[31] V. Alves,et al. Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection , 1996, Journal of Gastroenterology.
[32] Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.
[33] Huy A. Nguyen,et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.